first glp-1 drug Evolution of GLP‐1 Receptor Agonists for Diabetes Treatment Navigating the -tides: Medication-Assisted Weight

Pfizers dose-optimization studies of once-daily formulations of danuglipron ( NCT06567327 and NCT06568731 ) met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver a competitive efficacy and tolerability profile in Phase 3 testing, based on earlier studies of twice-daily danuglipron

Novo Nordisk is putting down up to US$362m to tap into Ascendis TransCon technology for treatments in metabolic and cardiovascular diseases

Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov

The effectiveness of its GIP receptor antagonism is still under investigation

Novo Nordisk scientist Lotte Bjerre Knudsen's discoveries helped kick off a revolution in how doctors think of and treat obesity.